Recombinant Human PTH1R/PTHR1 Protein, CF

Catalog #: 5709-PR Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
5709-PR-050

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human PTH1R/PTHR1 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human PTH1R/PTHR1 is used at 2 μg/mL, the concentration of biotinylated human PTHrP that produces 50% of the optimal binding response is found to be approximately 0.03 ‑ 0.12 μg/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human PTH1R/PTHR1 protein
Tyr23-Met189, with a C-terminal 6-His tag

Accession #

Q03431

N-terminal Sequence
Analysis

Tyr23

Predicted Molecular Mass

20.0 kDa

SDS-PAGE

25-40 kDa, reducing conditions

Product Datasheets

5709-PR

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

5709-PR

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 250 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: PTH1R/PTHR1

PTH1R (parathyroid receptor-1, also called PTHR1) is an 85-95 kDa member of the G-protein coupled receptor family 2 that is a critical receptor regulating Ca⁺⁺homeostasis (1-5). The human PTH1R cDNA encodes 593 amino acids (aa) including a 26 aa signal sequence and a long extracellular domain (aa 27-189) that contains the PTH (parathyroid hormone) and PTHrP (PTH-related protein) docking site (aa 173-189), followed by seven transmembrane domains within the C-terminal 404 aa (2-4). Within the N-terminal ECD, human PTH1R shares 87%, 88%, 96%, 94% and 93% aa identity with mouse, rat, canine, bovine and porcine PTH1R, respectively. PTH of other mammals will bind and stimulate human PTH1R, although with differing affinities (2). PTH1R is mainly expressed in bone and kidney, but is also present on hepatocytes, smooth muscle cells, and in other tissues where PTH and PTHrP are found (1-3, 5, 6). Through PTH1R on osteoblasts, PTH promotes differentiation of osteoclasts, which in turn promote release of Ca⁺⁺from bone (1, 5). PTH1R on osteocytes, however, allows PTH to promote bone formation (7). In renal epithelium, it promotes conversion of Vitamin D to its active form, lowers Ca⁺⁺excretion and increases phosphate excretion (1, 5). Following PTH binding, PTH1R undergoes a conformation change which activates cAMP, IP3, PKC and Ca⁺⁺signaling pathways (1, 8). PTH1R is then phosphorylated and downregulated by internalization (9). Dwarfism in Jansen‑type metaphyseal chondrodysplasia is associated with PTH1R gain of function, while in Blomstrand chondrodysplasia, PTH1R function is lost (10, 11). Impaired PTH1R function may be a factor in developmental endochondromas in Ollier disease (12). Polymorphisms may also be associated with variation in bone mineral density (13).

References

Potts, J.T. (2005) J. Endocrinol. 187:311.
Schipani, E. et al. (1993) Endocrinology 132:2157.
Zhou, A.T. et al. (1997) Proc. Natl. Acad. Sci. USA 94:3644.
Pellegrini, M. et al. (1998) Biochemistry 37:12737.
Lupp, A. et al. (2010) Eur. J. Endocrinol. 162:979.
Watson, P.H. et al. (2000) J. Bone Miner. Res. 15:1033.
O’Brien, C.A. et al. (2008) PLoS ONE 3:e2942.
Thomas, B.E. et al. (2008) Mol. Endocrinol. 22:1154.
Bounoutas, G.S. et al. (2006) Endocrinology 147:4674.
Schipani, E. et al. (1995) Science 268:98.
Wysolmerski, J.J. (2001) J. Clin. Endocrinol. Metab. 86:1788.
Couvineau, A. et al. (2008) Hum. Mol. Genet. 17:2766.
Vilarino-Guell, C. et al. (2007) Calcif Tissue Int. 81:270.

Long Name

Parathyroid Hormone Receptor 1

Entrez Gene IDs

5745 (Human); 19228 (Mouse); 56813 (Rat)

Alternate Names

MGC138426; parathyroid hormone 1 receptorMGC138452; parathyroid hormone/parathyroid hormone-related peptide receptor; parathyroid hormone/parathyroid hormone-related protein receptor; PFE; PTH/PTHr receptor; PTH/PTHrP type I receptor; PTH1 receptor; PTH1R; PTHR; PTHR1; PTHRPTHR1parathyroid hormone receptor 1; seven transmembrane helix receptor